SunBio,Inc.
Financials
Valuation Metrics
SunBio,Inc.'s Market Cap is ₩793B. At end of 2025 it was ₩694B. Ranked #1390 of 2,436 in KR market (top 57%), #781 of 1,649 on KOSDAQ (top 47%), #154 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 66%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 79.27B KRW | KR#1,390/2,436 Sec#154/234 |
| Revenue | 11.94B KRW | KR#2,264/2,436 Sec#172/234 |
| Net Income | 2.50B KRW | KR#1,315/2,436 Sec#92/234 |
| Total Assets | 62.27B KRW | KR#2,060/2,436 Sec#179/234 |
| Net Assets | 29.19B KRW | KR#2,172/2,436 Sec#195/234 |
| Employees | 23 | KR#2,214/2,436 Sec#206/234 |
| Value | ||
| P/E | 31.76x | KR#1,267/2,436 Sec#78/234 |
| P/B | 2.72x | KR#2,075/2,436 Sec#162/234 |
| P/S | 6.64x | KR#2,202/2,436 Sec#147/234 |
| EV/EBITDA | 24.27x | KR#1,103/2,436 Sec#67/234 |
| FCF Yield | 0.73% | KR#1,162/2,436 Sec#85/234 |
| Profitability | ||
| ROE | 8.55% | KR#640/2,436 Sec#39/234 |
| ROA | 4.01% | KR#788/2,436 Sec#69/234 |
| Op. Margin | 36.06% | KR#30/2,436 Sec#8/234 |
| Revenue Growth | -57.37% | KR#2,302/2,436 Sec#204/234 |
| Earnings Growth | -48.31% | KR#1,190/2,436 Sec#77/234 |
| Financial Health | ||
| Debt Ratio | 213.32% | KR#1,801/2,436 Sec#196/234 |
| Total Debt | 30.61B KRW | KR#1,184/2,436 Sec#91/234 |
| FCF | 576.6M KRW | KR#1,171/2,436 Sec#88/234 |
| Cash | 5.42B KRW | KR#1,958/2,436 Sec#174/234 |
| Current Ratio | 0.41x | KR#2,292/2,436 Sec#225/234 |
| Net Debt/EBITDA | 5.85x | KR#1,133/2,436 Sec#86/234 |
| Performance | ||
| 1Y Return | -4.42% | KR#813/2,436 Sec#61/234 |
| 1M Return | -2.11% | KR#1,116/2,436 Sec#106/234 |
| From 52W High | -23.65% | KR#241/2,436 Sec#14/234 |
| 1Y MDD | -38.19% | KR#460/2,436 Sec#35/234 |
| Trading | ||
| Volume | 10,392 shares | KR#2,103/2,436 Sec#209/234 |
| Foreign Own. | 0.45% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | 203 KRW | KR#1,195/2,436 Sec#83/234 |
| BPS | 2,400 KRW | KR#1,936/2,436 Sec#157/234 |
Company Info
Seonbio, established in 1997 and listed on KOSDAQ in 2022 as a technology growth company, specializes in the research, development, production, and sales of biopharmaceuticals, medical devices, and PEG derivatives. Utilizing its PEGylation technology, the company has commercialized various biopharmaceuticals, biosimilar drugs, and medical devices. Its neutropenia treatment Pegfilgrastim biosimilar is sold in the EU, Canada, Australia, and India, while the dry mouth treatment MucoPEG received US FDA sales approval in 2019.